Literature DB >> 23736647

Surgery: Cetuximab--an option for unresectable CRC liver metastases.

Pierre Laurent-Puig1, Leonor Benhaim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23736647     DOI： 10.1038/nrclinonc.2013.93

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

2.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Authors:  Pierre Laurent-Puig; Anne Cayre; Gilles Manceau; Emmanuel Buc; Jean-Baptiste Bachet; Thierry Lecomte; Philippe Rougier; Astrid Lievre; Bruno Landi; Valérie Boige; Michel Ducreux; Marc Ychou; Fréderic Bibeau; Olivier Bouché; Julia Reid; Steven Stone; Frédérique Penault-Llorca
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

3.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

4.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

5.  Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Authors:  Marc Peeters; Kelly S Oliner; Alex Parker; Salvatore Siena; Eric Van Cutsem; Jing Huang; Yves Humblet; Jean-Luc Van Laethem; Thierry André; Jeffrey Wiezorek; David Reese; Scott D Patterson
Journal:  Clin Cancer Res       Date:  2013-01-16       Impact factor: 12.531

6.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

7.  Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

Authors:  T André; H Blons; M Mabro; B Chibaudel; J-B Bachet; C Tournigand; M Bennamoun; P Artru; S Nguyen; C Ebenezer; N Aissat; A Cayre; F Penault-Llorca; P Laurent-Puig; A de Gramont
Journal:  Ann Oncol       Date:  2012-10-05       Impact factor: 32.976

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

Authors:  Le-Chi Ye; Tian-Shu Liu; Li Ren; Ye Wei; De-Xiang Zhu; Sheng-Yong Zai; Qing-Hai Ye; Yiyi Yu; Bo Xu; Xin-Yu Qin; Jianmin Xu
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.